

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS	3	JAN 16	CA/CAPLUS Company Name Thesaurus enhanced and reloaded
NEWS	4	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS	5	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS	6	JAN 22	CA/CAPLUS updated with revised CAS roles
NEWS	7	JAN 22	CA/CAPLUS enhanced with patent applications from India
NEWS	8	JAN 29	PHAR reloaded with new search and display fields
NEWS	9	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	10	FEB 15	PATDPASPC enhanced with Drug Approval numbers
NEWS	11	FEB 15	RUSSIAPAT enhanced with pre-1994 records
NEWS	12	FEB 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS	13	FEB 26	MEDLINE reloaded with enhancements
NEWS	14	FEB 26	EMBASE enhanced with Clinical Trial Number field
NEWS	15	FEB 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS	16	FEB 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS	17	FEB 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases
NEWS	18	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS	19	MAR 16	CASREACT coverage extended
NEWS	20	MAR 20	MARPAT now updated daily
NEWS	21	MAR 22	LWPI reloaded
NEWS	22	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS	23	APR 02	JICST-EPLUS removed from database clusters and STN
NEWS	24	APR 30	GENBANK reloaded and enhanced with Genome Project ID field
NEWS	25	APR 30	CHEMCATS enhanced with 1.2 million new records
NEWS	26	APR 30	CA/CAPLUS enhanced with 1870-1889 U.S. patent records
NEWS	27	APR 30	INPADOC replaced by INPADOCDB on STN
NEWS	28	MAY 01	New CAS web site launched
NEWS	29	MAY 08	CA/CAPLUS Indian patent publication number format defined
NEWS	30	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS	31	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS	32	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS	33	MAY 21	CA/CAPLUS enhanced with additional kind codes for German patents
NEWS	34	MAY 22	CA/CAPLUS enhanced with IPC reclassification in Japanese patents
NEWS EXPRESS			NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:30:39 ON 11 JUN 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 14:30:52 ON 11 JUN 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 10 JUN 2007 HIGHEST RN 936909-28-3

DICTIONARY FILE UPDATES: 10 JUN 2007 HIGHEST RN 936909-28-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10539522b.str



chain nodes :
 11 13 14 15 16 17 18 19 20 21 22 23 24
 ring nodes :
 1 2 3 4 5 6 7
 chain bonds :
 1-11 2-22 2-23 3-21 4-13 5-20 6-18 6-19 13-14 13-24 14-15 14-16 14-17
 ring bonds :
 1-2 1-6 2-3 3-4 3-7 4-5 5-6 5-7
 exact/norm bonds :
 1-2 1-6 1-11 2-3 3-4 3-7 4-5 4-13 5-6 5-7 13-24
 exact bonds :
 2-22 2-23 3-21 5-20 6-18 6-19 13-14 14-15 14-16 14-17
 isolated ring systems :
 containing 1 :

G1:C,O,S

G2:C,H

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 11:CLASS 13:CLASS
 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS 21:CLASS
 22:CLASS 23:CLASS 24:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 C,O,S

G2 C,H

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 14:31:37 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 602 TO ITERATE

100.0% PROCESSED 602 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 10568 TO 13512

PROJECTED ANSWERS: 736 TO 1664

L2 50 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 14:31:43 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 11446 TO ITERATE

100.0% PROCESSED 11446 ITERATIONS

1336 ANSWERS

SEARCH TIME: 00.00.01

L3 1336 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.55

172.76

FILE 'CAPLUS' ENTERED AT 14:31:50 ON 11 JUN 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Jun 2007 VOL 146 ISS 25
FILE LAST UPDATED: 10 Jun 2007 (20070610/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3 full
L4 217 L3

=> s l4 and py<2002
21897371 PY<2002
L5 177 L4 AND PY<2002

=> d ibib abs hitstr 1-10

L5 ANSWER 1 OF 177 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:284138 CAPLUS

DOCUMENT NUMBER: 142:355256

TITLE: Preparation of tricyclic-substituted piperidinols and analogs as chemokine receptor antagonists

INVENTOR(S): Luly, Jay R.; Nakasato, Yoshisuke; Ohshima, Etsuo; Harriman, Geraldine C. B.; Carson, Kenneth G.; Ghosh, Shomir; Elder, Amy M.; Mattia, Karen M.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 194 pp., Cont.-in-part of U.S. Ser. No. 989,086, abandoned.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 7

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005070549	A1	20050331	US 2004-487168	20041007
US 7186729	B2	20070306		
US 6613905	B1	20030902	US 1998-148823	19980904
US 6329385	B1	20011211	US 1999-235102	19990121 <--
US 2002119973	A1	20020829	US 1999-362837	19990728
US 6509346	B2	20030121		
US 2002169155	A1	20021114	US 2001-989086	20011121
WO 2003045942	A2	20030605	WO 2002-US36953	20021113
WO 2003045942	A3	20030912		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,

FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
 CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 US 2007060592 A1 20070315 US 2006-595653 20061110
 AU 2007200261 A1 20070208 AU 2007-200261 20070123
 PRIORITY APPLN. INFO.:

US 1998-148823 A2 19980904
 US 1999-235102 A2 19990121
 US 1999-362837 A2 19990728
 US 2000-627886 B2 20000728
 US 2001-989086 B2 20011121
 WO 2002-US36953 W 20021113
 US 1998-10320 B2 19980121
 AU 2002-352772 A3 20021113
 US 2004-487168 A1 20041007

OTHER SOURCE(S): MARPAT 142:355256
 GI




- AB Therapeutically effective compds. I [Z = (un)substituted heterocyclic ring fused to one or more carbocyclic aromatic rings; n = 1-4; M = NR₂, CR₁R₂; R₁ = H, OH, N₃, etc.; R₂ = OH, halo, acyl, aryl, etc.; R₇₀, R₇₁ = H, OH, N₃, etc.; R₇₂, R₇₃ = O, N₂, halo, etc.] and II [Z, n are defined as above; R₂ = OH, halo, acyl, aryl, etc.] were prepared for treatment of diseases associated with aberrant leukocyte recruitment and/or activation (no data). I and II displayed chemokine binding activities with IC₅₀ values ranging from < 1 μM to < 1000 μM. Thus, the [([1]benzoxepino[2,3-b]pyridinylidene)propyl]piperidinol III was prepared in three steps by reaction of 5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one with cyclopropylmagnesium bromide in THF, followed by ring cleavage-dehydration-bromination with HBr, and addition of 4-(4-chlorophenyl)-4-hydroxypiperidine to the bromide in DMF. Major and minor isomers were separated. The pharmaceutical compns. comprising the compound I or II is disclosed.
- IT 324782-01-6P, [1]Benzoxepino[3,4-b]pyridin-7-ol, 5-[3-[3-(4-chlorophenyl)-3-hydroxy-8-azabicyclo[3.2.1]oct-8-yl]propylidene]-5,11-dihydro-
- RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
- (preparation of tricyclic piperidinols and pyrrolidines as chemokine

receptor antagonists for treatment of diseases associated with aberrant leukocyte recruitment and activation)

RN 324782-01-6 CAPLUS

CN [1]Benzoxepino[3,4-b]pyridin-7-ol, 5-[3-[3-(4-chlorophenyl)-3-hydroxy-8-azabicyclo[3.2.1]oct-8-yl]propylidene]-5,11-dihydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 151 THERE ARE 151 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 177 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:869579 CAPLUS

DOCUMENT NUMBER: 137:370077

TITLE: Preparation of tricyclic-substituted piperidinols and analogs as chemokine receptor antagonists

INVENTOR(S): Luly, Jay R.; Nakasato, Yoshisuke; Ohshima, Etsuo; Sone, Hiroki; Kotera, Osamu; Harriman, Geraldine C. B.; Carson, Kenneth G.

PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 138 pp., Cont.-in-part of U. S. Ser. No. 627,886.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 7

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002169155	A1	20021114	US 2001-989086	20011121
US 6613905	B1	20030902	US 1998-148823	19980904
US 6329385	B1	20011211	US 1999-235102	19990121 <--
US 2002119973	A1	20020829	US 1999-362837	19990728
US 6509346	B2	20030121		
CA 2467672	A1	20030605	CA 2002-2467672	20021113
WO 2003045942	A2	20030605	WO 2002-US36953	20021113
WO 2003045942	A3	20030912		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,

FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,				
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002352772	A1	20030610	AU 2002-352772	20021113
BR 2002013633	A	20040824	BR 2002-13633	20021113
EP 1448566	A2	20040825	EP 2002-789725	20021113
EP 1448566	B1	20060315		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
CN 1585772	A	20050223	CN 2002-827426	20021113
JP 2005510565	T	20050421	JP 2003-547392	20021113
HU 200500079	A2	20050428	HU 2005-79	20021113
AT 320431	T	20060415	AT 2002-789725	20021113
EP 1688418	A2	20060809	EP 2006-4401	20021113
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
PT 1448566	T	20060831	PT 2002-789725	20021113
ES 2260497	T3	20061101	ES 2002-2789725	20021113
CN 1911930	A	20070214	CN 2006-10105450	20021113
IN 2004DN01154	A	20050401	IN 2004-DN1154	20040429
ZA 2004003530	A	20050728	ZA 2004-3530	20040510
NO 2004002500	A	20040615	NO 2004-2500	20040615
HK 1063789	A1	20060811	HK 2004-106595	20040902
US 2005070549	A1	20050331	US 2004-487168	20041007
US 7186729	B2	20070306		
US 2007060592	A1	20070315	US 2006-595653	20061110
AU 2007200261	A1	20070208	AU 2007-200261	20070123
PRIORITY APPLN. INFO.:				
			US 1998-148823	A2 19980904
			US 1999-235102	A2 19990121
			US 1999-362837	A2 19990728
			US 2000-627886	A2 20000728
			US 1998-10320	B2 19980121
			US 2001-989086	A 20011121
			AU 2002-352772	A3 20021113
			CN 2002-827426	A3 20021113
			EP 2002-789725	A3 20021113
			WO 2002-US36953	W 20021113
			US 2004-487168	A1 20041007

OTHER SOURCE(S): MARPAT 137:370077
GI



AB Therapeutically effective compds. I [Z = (un)substituted cycloalkyl or non-aromatic heterocyclic ring fused to one or more carbocyclic aromatic rings; n = 1-4; M = NR₂, CR₁R₂, OCR₁R₂O, CH₂CR₁R₂O; R₁ = H, OH, N₃, etc.; R₂ = H, acyl, aryl, etc.; q₁ = 0-3; q₂ = 0-1; ring containing M is substituted or unsubstituted; and physiol. acceptable salts thereof] were prepared for treatment of diseases associated with aberrant leukocyte recruitment and/or activation (no data). I displayed chemokine binding activities with IC₅₀ values ranging from < 1 μM to < 1000 μM. Thus, the

[[([1]benzoxepino[2,3-b]pyridinylidene)propyl]piperidinol II was prepared in three steps by reaction of 5,11-dihydro-7-methoxy[1]benzoxepino[2,3-b]pyridin-5-one with cyclopropylmagnesium bromide in THF, followed by ring cleavage-dehydration-bromination with HBr, and addition of 4-(4-chlorophenyl)-4-hydroxypiperidine to the bromide in DMF. Major and minor isomers were separated


IT 324782-01-6P; [1]Benzoxepino[3,4-b]pyridin-7-ol, 5-[3-[3-(4-chlorophenyl)-3-hydroxy-8-azabicyclo[3.2.1]oct-8-yl]propylidene]-5,11-dihydro-

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of tricyclic piperidinols as chemokine receptor antagonists for treatment of diseases associated with aberrant leukocyte recruitment and activation)

RN 324782-01-6 CAPLUS

CN [1]Benzoxepino[3,4-b]pyridin-7-ol, 5-[3-[3-(4-chlorophenyl)-3-hydroxy-8-azabicyclo[3.2.1]oct-8-yl]propylidene]-5,11-dihydro- (9CI) (CA INDEX NAME)



L5 ANSWER 3 OF 177 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:658747 CAPLUS

DOCUMENT NUMBER: 137:185480

TITLE: Preparation of tricyclic-substituted piperidinols and analogs as chemokine receptor antagonists

INVENTOR(S): Luly, Jay R.; Nakasato, Yoshisuke; Ohshima, Etsuo; Sone, Hiroki; Kotera, Osamu; Harriman, Geraldine C. B.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 102 pp., Cont.-in-part of U.S. Ser. No. 235,102.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 7

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002119973	A1	20020829	US 1999-362837	19990728
US 6509346	B2	20030121		
US 6613905	B1	20030902	US 1998-148823	19980904
US 6329385	B1	20011211	US 1999-235102	19990121 <--
CA 2391267	A1	20010208	CA 2000-2391267	20000728 <--
WO 2001009138	A2	20010208	WO 2000-US20732	20000728 <--
WO 2001009138	A3	20010913		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1204665 A2 20020515 EP 2000-950880 20000728
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL
BR 2000013065 A 20020730 BR 2000-13065 20000728
HU 200202202 A2 20021128 HU 2002-2202 20000728
JP 2003506377 T 20030218 JP 2001-514341 20000728
US 2002169155 A1 20021114 US 2001-989086 20011121
US 2003045516 A1 20030306 US 2002-217865 20020813
WO 2003045942 A2 20030605 WO 2002-US36953 20021113
WO 2003045942 A3 20030912

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW



RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

HU 200500079 A2 20050428 HU 2005-79 20021113
US 2005070549 A1 20050331 US 2004-487168 20041007
US 7186729 B2 20070306
AU 2007200261 A1 20070208 AU 2007-200261 20070123

PRIORITY APPLN. INFO.:

US 1998-10320 B2 19980121
US 1998-148823 A2 19980904
US 1999-235102 A2 19990121
US 1999-362837 A 19990728
US 2000-627886 A2 20000728
WO 2000-US20732 W 20000728
US 2001-989086 A2 20011121
AU 2002-352772 A3 20021113
WO 2002-US36953 W 20021113

OTHER SOURCE(S): MARPAT 137:185480
GI



AB Disclosed is a method of treating a subject with a disease associated with aberrant leukocyte recruitment and/or activation. Therapeutically effective tricyclic-substituted piperidinols and analogs thereof, represented by structural formula I [M = CR₁R₂ where R₁ = H, OH, alkyl, (un)substituted alkoxy, SR₃; R₃ = H or substituted alkyl, (un)substituted alkylcarboxy, alkoxy carbonyl, CN, COOH, CONR₄R₅; R₂ = OH, (un)substituted acyl, NR₆R₇, (un)substituted alkyl, aryl, etc.; R₄-7 = H, (un)substituted acyl, aliphatic aromatic, heterocycle, etc., or, R₁, R₂, R₄ and R₅, or R₆ and

R₇ taken together with the atom to which they are bonded form a (un)substituted carbocyclic or heterocyclic ring; Z = (un)substituted cycloalkyl or non-aromatic heterocyclic ring fused to one or more carbocyclic aromatic rings; n = 1-4] and their physiol. acceptable salts are prepared Chemokine binding activities of test compds. are reported with IC₅₀ values ranging from <1 to <1000 μM. Thus, II was prepared via substitution of 5-(3-bromopropylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene with 4-(4-chlorophenyl)-4-hydroxypiperidine.


IT 324782-01-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of tricyclic-substituted piperidinols and analogs as chemokine receptor antagonists for treatment of diseases associated with aberrant leukocyte recruitment and activation)

RN 324782-01-6 CAPLUS


CN [1]Benzoxepino[3,4-b]pyridin-7-ol, 5-[3-[3-(4-chlorophenyl)-3-hydroxy-8-azabicyclo[3.2.1]oct-8-yl]propylidene]-5,11-dihydro- (9CI) (CA INDEX NAME)



L5 ANSWER 4 OF 177 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2002:462644 CAPLUS
 DOCUMENT NUMBER: 137:6174
 TITLE: Azabicycloalkyl esters and amides of
 2-oxo-2,3-dihydrobenzimidazole-1-carboxylic acid and
 their preparation, pharmaceutical compositions, and
 use as 5-HT₄ receptor agonists
 INVENTOR(S): Pellegrini, Carlo Maria; Cereda, Enzo; Ezhaya,
 Antoine; Schiavi, Giovanni Battista; Sagrata, Angelo;
 Giraldo, Ettore
 PATENT ASSIGNEE(S): Boehringer Ingelheim Italia S.p.A., Italy
 SOURCE: Ital., 62 pp.
 CODEN: ITXXBY
 DOCUMENT TYPE: Patent
 LANGUAGE: Italian
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IT 1298271	B1	19991220	IT 1998-MI305	19980218 <--
PRIORITY APPLN. INFO.:			IT 1998-MI305	19980218
OTHER SOURCE(S):	MARPAT	137:6174		

GI



AB Title compds. I are disclosed [wherein: R = H, Me; Y = O, NH; Z = CH₂, bond; n = 0, 1, 2, 3, except that when R₁ = H, then n ≠ 0 or 1; R₁ = H, iso-Pr, Et, iso-Bu, cyclopropyl, cyclobutyl, cyclohexyl, vinyl, 2-methylpropenyl, 1-hydroxyethyl, ethynyl, benzyl, CONH₂, CONMe₂, COCH₃, cyano, OR₂, SR₂, NR₃R₄; R₂ = H, C1-3 alkyl; R₃ = H, CH₃, CONHEt, CONH₂, CO₂Et, COCH₃, SO₂Me; R₄ = H, Me; including racemates, enantiomers,

diastereomers, mixts., and physiol. acceptable acid addition salts]. The compds. are serotonergic agonists, and have a high affinity and specificity for 5-HT₄ serotonergic receptors. As such they are useful for treating a variety of cardiovascular, gastrointestinal, and CNS diseases and disorders. Over 60 compds., including both esters (Y = O) and amides (Y = NH), were prepared. For instance, 1-isopropyl-2-oxo-2,3-dihydrobenzimidazole was treated with Cl₃COCOC₃Cl in THF to give the 1-carbonyl chloride derivative, which reacted with endo-8-n-propyl-8-azabicyclo[3.2.1]octan-3-ol (preparation given) in CH₂Cl₂ to give title compound

II [Q = n-Pr], isolated as the HCl salt. The similarly prepared compound II.HCl [Q = iso-Bu] bound to porcine striatal 5-HT₄ receptors in vitro with a K_i of 3.6 + 10⁻⁸ M, but bound to 5-HT₃ receptors (NG 108-15 cells) with a weaker K_i of 446 + 10⁻⁸ M. Selected I also induced contractions in isolated guinea pig colon, with an efficacy comparable to 5-HT, and with blocking by the known 5-HT₄ antagonist GR 113808.

IT 433226-62-1P, endo-8-n-Propyl-8-azabicyclo[3.2.1]oct-3-yl 3-isopropyl-2-oxo-2,3-dihydrobenzimidazole-1-carboxylate hydrochloride
 433226-68-7P, endo-8-n-Propyl-8-azabicyclo[3.2.1]oct-3-yl 3-ethyl-2-oxo-2,3-dihydrobenzimidazole-1-carboxylate hydrochloride
 433226-74-5P, endo-8-(3-Methylbutyl)-8-azabicyclo[3.2.1]oct-3-yl 3-isopropyl-2-oxo-2,3-dihydrobenzimidazole-1-carboxylate hydrochloride
 433226-75-6P, endo-8-n-Butyl-8-azabicyclo[3.2.1]oct-3-yl 3-isopropyl-2-oxo-2,3-dihydrobenzimidazole-1-carboxylate hydrochloride
 433227-48-6P, endo-8-n-Propyl-8-azabicyclo[3.2.1]oct-3-yl 3-ethyl-2-oxo-2,3-dihydrobenzimidazole-1-carboxylate


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of azabicycloalkyl esters and amides of oxodihydrobenzimidazolecarboxylic acid as 5-HT₄ receptor agonists)

RN 433226-62-1 CAPLUS

CN 1H-Benzimidazole-1-carboxylic acid, 2,3-dihydro-3-(1-methylethyl)-2-oxo-, (3-endo)-8-propyl-8-azabicyclo[3.2.1]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 433226-68-7 CAPLUS

CN 1H-Benzimidazole-1-carboxylic acid, 3-ethyl-2,3-dihydro-2-oxo-, (3-endo)-8-propyl-8-azabicyclo[3.2.1]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 433226-74-5 CAPLUS

CN 1H-Benzimidazole-1-carboxylic acid, 2,3-dihydro-3-(1-methylethyl)-2-oxo-, (3-endo)-8-(3-methylbutyl)-8-azabicyclo[3.2.1]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 433226-75-6 CAPLUS

CN 1H-Benzimidazole-1-carboxylic acid, 2,3-dihydro-3-(1-methylethyl)-2-oxo-, (3-endo)-8-butyl-8-azabicyclo[3.2.1]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 433227-48-6 CAPLUS
 CN 1H-Benzimidazole-1-carboxylic acid, 3-ethyl-2,3-dihydro-2-oxo-,
 (3-endo)-8-propyl-8-azabicyclo[3.2.1]oct-3-yl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



IT 22226-44-4P, endo-8-Isopentyl-8-azabicyclo[3.2.1]octan-3-ol
 60205-27-8P, endo-8-Propyl-8-azabicyclo[3.2.1]octan-3-ol
 60205-34-7P, endo-8-Butyl-8-azabicyclo[3.2.1]octan-3-ol
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (intermediate; preparation of azabicycloalkyl esters and amides of
 oxodihydrobenzimidazolecarboxylic acid as 5-HT4 receptor agonists)


RN 22226-44-4 CAPLUS
 CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-(3-methylbutyl)-, (3-endo)- (9CI) (CA
 INDEX NAME)

Relative stereochemistry.




RN 60205-27-8 CAPLUS
 CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-propyl-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 60205-34-7 CAPLUS
 CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-butyl-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L5 ANSWER 5 OF 177 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2001:817246 CAPLUS
 DOCUMENT NUMBER: 135:357843
 TITLE: Preparation of 2-Aryl indole derivatives for use as tachykinin receptor antagonists
 INVENTOR(S): Dinnell, Kevin; Elliott, Jason Matthew; Hollingworth, Gregory John; Ridgill, Mark Peter; Shaw, Duncan Edward
 PATENT ASSIGNEE(S): UK
 SOURCE: U.S. Pat. Appl. Publ., 37 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2001039286	A1	20011108	US 2001-782422	20010213 <--
PRIORITY APPLN. INFO.:			GB 2000-3397	A 20000214
OTHER SOURCE(S):	MARPAT 135:357843			
GI				



AB 2-Aryl indole derivs. I (wherein R1a, R1b, and R2 = a variety of substituents; R3 = optionally substituted Ph, biphenyl or naphthyl or heteroaryl group; R4 = H, (C1-6)alkyl, carbonyl (=O), (CH2)pphenyl or a (C1-2)alkylene bridge across the piperidine ring; R5 and R6 = variety of substituents; or R5 and R6 together are linked so as to form an optionally substituted 5-or 6-membered ring; X = O or S, two H atoms, boxHNH or boxHN(C1-6 alkyl); Y = straight or branched (C1-4)alkylene, (C2-4)alkenylene or (C2-4)alkynylene chain; the dotted line represents an optional double bond; m = 0,1,2,3,4; n = 1,2,3,4; and p = 1,2,3,4), or a pharmaceutically acceptable salt thereof, were prepared, and their use as tachykinin receptor antagonists evaluated. Thus, diisopropylethylamine and bromoacetonitrile were added to a loaded resin (synthetic preparation given) in N-methylpyrrolidinone, to which was added a solution of 6-(methylsulfonyl)spiro-[2H-1-benzopyran-2,4'-piperidin]-4(3H)-one in THF to give 1'-{3-[5-chloro-2-(4-chlorophenyl)-1H-indol-3-yl]-1-oxopropyl}-6-(methylsulfonyl)spiro(2H-1-benzopyran-2,4'-piperidin)-4(3H)-one. The compds. are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis or postherpetic neuralgia. Biol. data are given.

IT 371970-31-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of aryl indole derivs. as tachykinin receptor antagonists for treatment for)
 RN 371970-31-9 CAPLUS

CN 8-Azabicyclo[3.2.1]octane, 8-[3-[5-chloro-2-(4-chlorophenyl)-1-methyl-1H-indol-3-yl]propyl]-3-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 6 OF 177 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:785490 CAPLUS

DOCUMENT NUMBER: 136:85971

TITLE: Novel tropane-based irreversible ligands for the dopamine transporter

AUTHOR(S): Zou, Mu-Fa; Kopajtic, Theresa; Katz, Jonathan L.; Wirtz, Sara; Justice, Joseph B., Jr.; Newman, Amy Hauck

CORPORATE SOURCE: Medicinal Chemistry and Psychobiology Sections, National Institute on Drug Abuse-Intramural Research Program, Baltimore, MD, 21131, USA

SOURCE: Journal of Medicinal Chemistry (2001), 44(25), 4453-4461

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 136:85971

AB 3 α -(Diphenylmethoxy)tropane (bentropine) and its analogs are tropane ring-containing dopamine uptake inhibitors that display binding and behavioral profiles that are distinct from cocaine. The authors previously prepared a bentropine-based photoaffinity label [125I]-N-[4-(4'-azido-3'-iodophenyl)butyl]-3 α -[bis(4'-fluorophenyl)methoxy]tropane, (I), that covalently attached to the 1-2 transmembrane spanning region of the dopamine transporter (DAT). This was in contrast to the 4-7 transmembrane spanning region labeled by a cocaine-based photoaffinity label, (RTI 82) (II). To characterize further these different binding domains, photoaffinity ligands that had the 4'-azido-3'-iodophenyl substituent extended from the same position on the tropane ring were desirable. Thus, identification of the optimal alkyl linker between this substituent and the tropane nitrogen in the bentropine series was investigated to ultimately prepare the identical N-substituted analog of II. In this pursuit, the N-[4-(4'-azido-3'-iodophenyl)propyl] analog of 3 α -[bis(4'-fluorophenyl)methoxy]tropane was synthesized as well as two isothiocyanate analogs that do not require photoactivation for irreversible binding. The synthesis of these target compds. was achieved using a modification of the strategy developed for I. Evaluation of these compds. for displacing [3H]WIN 35 428 binding at DAT in rat caudate putamen revealed that the 4'-azido-3'-iodophenylbutyl substituent, found in I, provided optimal binding affinity and was chosen to replace the N-CH₃ group on II. Both the 4'-azido-3'-iodophenyl- and the 4'-isothiocyanatophenylbutyl analogs of II were synthesized. Both products bound to DAT with comparable potency (IC₅₀ = 30 nM) to RTI 82. In addition, the 4'-isothiocyanatophenylbutyl analog of II demonstrated wash-resistant displacement of [3H]WIN 35 428 in HEK 293 cells stably transfected with hDAT. These ligands will provide important tools for further characterizing the binding domains for tropane-based dopamine uptake inhibitors at the DAT.


IT 387357-10-0P 387357-11-1P 387357-19-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
(Biological study); PREP (Preparation)
(preparation and dopamine transporter binding of tropane-based irreversible
ligands with interest in developing cocaine abuse treatment)

RN 387357-10-0 CAPLUS

CN 8-Azabicyclo[3.2.1]octane, 8-[3-(4-azido-3-iodophenyl)propyl]-3-[bis(4-fluorophenyl)methoxy]-, (3-endo)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 387357-11-1 CAPLUS

CN 8-Azabicyclo[3.2.1]octane, 3-[bis(4-fluorophenyl)methoxy]-8-[3-(4-isothiocyanatophenyl)propyl]-, (3-endo)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 387357-19-9 CAPLUS

CN 8-Azabicyclo[3.2.1]octane, 3-[bis(4-fluorophenyl)methoxy]-8-[4-(4-isothiocyanatophenyl)butyl]-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 203048-97-9P 387357-08-6P 387357-09-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and dopamine transporter binding of tropane-based irreversible ligands with interest in developing cocaine abuse treatment)

RN 203048-97-9 CAPLUS

CN Benzenamine, 4-[4-[(3-endo)-3-[bis(4-fluorophenyl)methoxy]-8-azabicyclo[3.2.1]oct-8-yl]butyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 387357-08-6 CAPLUS

CN Benzenamine, 4-[3-[(3-endo)-3-[bis(4-fluorophenyl)methoxy]-8-azabicyclo[3.2.1]oct-8-yl]propyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 387357-09-7 CAPLUS

CN Benzenamine, 4-[3-[(3-endo)-3-[bis(4-fluorophenyl)methoxy]-8-azabicyclo[3.2.1]oct-8-yl]propyl]-2-iodo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 387357-17-7P 387357-18-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and dopamine transporter binding of tropane-based irreversible ligands with interest in developing cocaine abuse treatment)

RN 387357-17-7 CAPLUS


CN 8-Azabicyclo[3.2.1]octane, 8-[3-(4-azido-3-iodophenyl)propyl]-3-[bis(4-fluorophenyl)methoxy]-, (3-endo)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 387357-10-0


CMF C29 H29 F2 I N4 O

Relative stereochemistry.




CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 387357-18-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-[bis(4-fluorophenyl)methoxy]-8-[3-(4-isothiocyanatophenyl)propyl]-, monohydrochloride, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 177 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:749720 CAPLUS
DOCUMENT NUMBER: 136:37802
TITLE: Synthesis and biological evaluation of tropane-like

1-{2-[bis(4-fluorophenyl)methoxy]ethyl}-4-(3-phenylpropyl)piperazine (GBR 12909) analogs

AUTHOR(S): Zhang, Ying; Joseph, David B.; Bowen, Wayne D.; Flippen-Anderson, Judith L.; Dersch, Christina M.; Rothman, Richard B.; Jacobson, Arthur E.; Rice, Kenner C.

CORPORATE SOURCE: Laboratory of Medicinal Chemistry National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, 20892-0815, USA

SOURCE: Journal of Medicinal Chemistry (2001), 44(23), 3937-3945
CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 136:37802


AB The authors have prepared azabicyclo[3.2.1] derivs. (C-3-substituted tropanes) that bind with high affinity to the dopamine transporter and inhibit dopamine reuptake. Within the series, 3-{2-[bis-(4-fluorophenyl)methoxy]ethylidene}-8-methyl-8-azabicyclo[3.2.1]octane (I) was found to have the highest affinity and selectivity for the dopamine transporter. These azabicyclo[3.2.1] (bridged piperidine) series of compds. differ from the well-known benztropines by a 2-carbon spacer between C-3 and a diarylmethoxy moiety. Interestingly, these new compds. demonstrated a much lower affinity for the muscarinic-1 site, at least a 100-fold decrease compared to benztropine. Interestingly, these new compds. demonstrated a much lower affinity for the muscarinic-1 site, at least a 100-fold decrease compared to benztropine. Replacing N-Me with N-phenylpropyl in two of the compds. resulted in a 3-10-fold increase in binding affinity for the dopamine transporter. However, those compds. lost selectivity for the dopamine transporter over the serotonin transporter. Replacement of the ether oxygen in the diarylmethoxy moiety with a nitrogen atom gave relatively inactive amines, indicating the important role which is played by the ether oxygen in transporter binding. Reduction of the C-3 double bond in I gave 3 α -substituted tropanes, as shown by X-ray crystallog. analyses. The 3 α -substituted tropanes had lower affinity and less selectivity than the comparable unsatd. ligands.

IT 380602-02-8P 380602-03-9P
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (preparation, muscarinic M1 receptor, dopamine and serotonin transporter affinity, and structure-activity relationship of azabicyclooctane derivs. as GBR 12909 analogs)

RN 380602-02-8 CAPLUS

CN 8-Azabicyclo[3.2.1]octane, 3-[2-(diphenylmethoxy)ethyl]-8-(3-phenylpropyl)-, hydrochloride, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 380602-03-9 CAPLUS

CN 8-Azabicyclo[3.2.1]octane, 3-[2-[bis(4-fluorophenyl)methoxy]ethyl]-8-(3-phenylpropyl)-, hydrochloride, (3'-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 177 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:574757 CAPLUS

DOCUMENT NUMBER: 135:303847

TITLE: Design and Synthesis of [(2,3-Dichlorophenyl)piperazin-1-yl]alkylfluorenylcarboxamides as Novel Ligands Selective for the Dopamine D3 Receptor Subtype

AUTHOR(S): Robarge, Michael J.; Husbands, Stephen M.; Kieltyka, Andrzej; Brodbeck, Robbin; Thurkauf, Andrew; Newman, Amy Hauck

CORPORATE SOURCE: Medicinal Chemistry Section, National Institute on Drug Abuse-Intramural Research Program, Baltimore, MD, 21224, USA

SOURCE: Journal of Medicinal Chemistry (2001), 44(19), 3175-3186

CODEN: JMCMAR; ISSN: 0022-2623


PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 135:303847

GI



I

AB The dopamine D3 receptor subtype has been recently targeted as a potential neurochem. modulator of the behavioral actions of psychomotor stimulants, such as cocaine. However, definitive behavioral investigations have been hampered by the lack of highly selective D3 agonists and antagonists. In

an attempt to design a novel class of D3 ligands with which to study this receptor system, a series of chemical divergent compds. that possessed various structural features that exist within several classes of reputed D3 agents was screened and compared to the recently reported NGB 2904. On the basis of these results, a novel series of compds. was designed that included functional moieties that were required for high-affinity and selective binding to D3 receptors. All the compds. in this series included an aryl-substituted piperazine ring, a varying alkyl chain linker (C3-C5), and a terminal aryl amide. The compds. were synthesized and evaluated in vitro for binding in CHO cells transfected with human D2, D3, or D4 receptor cDNAs. D3 binding affinities ranged from $K_i = 1.4$ to 1460 nM. The most potent analog in this series, I, demonstrated a D3/D2 selectivity of 64 and a D3/D4 selectivity of 1300. Structure-activity relationships for this class of ligands at D3 receptors will provide new leads toward the development of highly selective and potent mol. probes that will prove useful in the elucidation of the role D3 receptors play in the psychomotor stimulant and reinforcing properties of cocaine.


IT 264869-03-6 367275-32-9

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of [(2,3-dichlorophenyl)piperazin-1-yl]alkylfluorenylcarboxamides as ligands selective for the dopamine D3 receptor)

RN 264869-03-6 CAPLUS

CN 8-Azabicyclo[3.2.1]octane, 3-[bis(4-fluorophenyl)methoxy]-8-(4-phenylbutyl)-, (3-endo)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 367275-32-9 CAPLUS

CN 8-Azabicyclo[3.2.1]octane, 3-[(3-chlorophenyl)phenylmethoxy]-8-(3-phenylpropyl)-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.





REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 177 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:560064 CAPLUS

DOCUMENT NUMBER: 135:137519
 TITLE: Preparation of 1-(4-arylpiperidinopropyl)carbamoyl-2-piperidone-5-carboxylates and analogs as α 1c antagonists
 INVENTOR(S): Nagarathnam, Dhanapalan; Chiu, George; Dhar, T. G. Murali; Wong, Wai C.; Marzabadi, Mohammad R.; Gluchowski, Charles; Lagu, Bharat; Miao, Shou Wu
 PATENT ASSIGNEE(S): Synaptic Pharmaceutical Corp., USA
 SOURCE: U.S., 67 pp., Cont.-in-part of U. S. Ser. No. 340,611, abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6268369	B1	20010731	US 1997-836628	19970516 <--
WO 9614846	A1	19960523	WO 1995-US15025	19951116 <--
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6248747	B1	20010619	US 1999-291553	19990414 <--
US 6727257	B1	20040427	US 2000-730458	20001205
PRIORITY APPLN. INFO.:			US 1994-340611	B2 19941116
			WO 1995-US15025	W 19951116
			US 1997-836628	A1 19970516
			US 1997-978682	A3 19971126
OTHER SOURCE(S):		MARPAT 135:137519		
GI				



AB Title compds. [e.g., I; R = (un)substituted (hetero)aryl; R1 = H, (fluoro)alkyl, cyano, CO2R3, etc.; R2 = H, alkyl, OR3, etc.; R3 = H, (fluoro)alkyl, etc.; R4 = e.g., (4-arylpiperidinopropyl)carbamoyl; X = O,


S, (alkyl)imino] and analogs thereof were prepared Over 60 synthetic examples were provided. Thus 1,6-dihydro-5-(cyanoethoxycarbonyl)-4-ethyl-6-(4-nitrophenyl)-2-methoxypyrimidine (prepared in 3 steps) was treated with 4-nitrophenylchloroformate (acylation at N1) followed by the corresponding substituted piperidine to give the N1 carboxamide intermediate. The cyanoethoxycarbonyl function was saponified and converted to the 5-carboxamido derivative II. Thus, title compound II had pKi of 9.74 for binding at human α lc receptors in vitro. Treatment of benign prostatic hyperplasia is a claimed use of the invention.

IT 179481-64-2P 179481-65-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1-(4-arylpiperidinopropyl)carbamoyl-2-piperidone-5-carboxylates and analogs as α lc antagonists)


RN 179481-64-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 6-(3,4-difluorophenyl)-1,2,3,6-tetrahydro-1-[[[3-(3-hydroxy-3-phenyl-8-azabicyclo[3.2.1]oct-8-yl)propyl]amino]carbonyl]-4-methyl-2-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 179481-65-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 6-(3,4-difluorophenyl)-1,2,3,6-tetrahydro-1-[[[3-(3-hydroxy-3-phenyl-8-azabicyclo[3.2.1]oct-8-yl)propyl]amino]carbonyl]-4-methyl-2-oxo-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl



REFERENCE COUNT:

67

THERE ARE 67 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2001:338355 CAPLUS
 DOCUMENT NUMBER: 134:340509
 TITLE: Preparation of 8-azabicyclo[3.2.1]octane NMDA/NR2B antagonists
 INVENTOR(S): Thompson, Wayne; Claremon, David A.; Munson, Peter M.; Phillips, Brian
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA
 SOURCE: PCT Int. Appl., 77 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001032179	A1	20010510	WO 2000-US29479	20001026 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6432976	B1	20020813	US 2000-696503	20001025
CA 2388171	A1	20010510	CA 2000-2388171	20001026 <--
EP 1244450	A1	20021002	EP 2000-979131	20001026
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003513044	T	20030408	JP 2001-534384	20001026
PRIORITY APPLN. INFO.:			US 1999-162718P	P 19991029
			WO 2000-US29479	W 20001026
OTHER SOURCE(S):			MARPAT 134:340509	
GI				



AB The title compds., commonly known as tropanes, (I) [wherein R1 = (un)substituted 2-benzimidazole, imidazole, imidazopyridine, indole, quinazoline, purine, benzoxazolone, or phenol; R2 = Ph, optionally substituted with 1-5 substituents selected from Cl, F, Br, alkyl, CF3, OH, or CO2H; L1 and L2 = independently (cyclo)alkyl, alkenyl, alkynyl, alkoxy, aminoalkyl, hydroxyalkyl, or (amino)carbonyl; X = OH, NH2, (di)alkylamino,

alkyl, ester, carbamate, carbonate, or ether] were prepared as effective NMDA NR2B glutamate receptor antagonists. For example, addition of di-Et 4-chlorobenzylphosphonate to N-carbethoxy-4-tropinone to give the benzylidene, reduction using Pt/C, N-deprotection using HBr in AcOH, and reductive addition of 1-(trimethylsilylethoxymethyl)-1H-benzimidazole-2-carbaldehyde (2-step preparation given) using NaBH(OAc)3 in ClCH2CH2Cl afforded exo-II. Exptl. protocols for assessing the inhibition of NR1A/2B NMDA receptor activation (FLIPR assay) and determining the apparent dissociation

consts.

against the human NR1A/NR2B receptor (binding assay) are given (no data). I are useful for relieving pain and treating migraine, depression, anxiety, schizophrenia, Parkinson's disease, or stroke (no data).

IT 338733-30-5P 338733-34-9P 338733-35-0P
338733-37-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of (benzimidazolylalkyl)tropane NMDA/NR2B antagonists for treatment of pain)

RN 338733-30-5 CAPLUS


CN 8-Azabicyclo[3.2.1]octane, 8-[3-[4-(phenylmethoxy)phenyl]propyl]-3-(phenylmethyl)-, (3-exo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 338733-34-9 CAPLUS

CN 1H-Benzimidazole-1-propanenitrile, 2-[3-[3-(phenylmethyl)-8-azabicyclo[3.2.1]oct-8-yl]propyl]- (9CI) (CA INDEX NAME)




RN 338733-35-0 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-8-butanoic acid, 3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 338733-37-2 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-8-butanoic acid, 3-(phenylmethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)




IT 338732-79-9P 338732-81-3P 338732-86-8P
 338732-89-1P 338732-91-5P 338732-92-6P
 338733-09-8P 338733-10-1P 338733-13-4P
 338733-16-7P 338795-47-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of (benzimidazolylalkyl)tropane NMDA/NR2B antagonists for treatment of pain)

RN 338732-79-9 CAPLUS

CN 8-Azabicyclo[3.2.1]octane, 8-[3-(1H-imidazol-4-yl)propyl]-3-(phenylmethyl)-, (3-exo)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 338732-81-3 CAPLUS

CN Phenol, 4-[3-[(3-exo)-3-(phenylmethyl)-8-azabicyclo[3.2.1]oct-8-yl]propyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 338732-86-8 CAPLUS

CN Phenol, 4-[3-[(3-exo)-3-[(4-chlorophenyl)methyl]-8-azabicyclo[3.2.1]oct-8-yl]propyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 338732-89-1 CAPLUS


CN Phenol, 4-[3-[(3-exo)-3-(phenylmethyl)-8-azabicyclo[3.2.1]oct-8-yl]butyl]-
(9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 338732-91-5 CAPLUS

CN 8-Azabicyclo[3.2.1]octane, 8-[3-(1H-benzimidazol-2-yl)propyl]-3-
(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 338732-92-6 CAPLUS

CN 8-Azabicyclo[3.2.1]octane, 8-[3-(1H-imidazo[4,5-b]pyridin-2-yl)propyl]-3-
(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 338733-09-8 CAPLUS

CN 8-Azabicyclo[3.2.1]octane, 8-[3-(1H-imidazol-4-yl)propyl]-3-(phenylmethyl)-
(9CI) (CA INDEX NAME)




RN 338733-10-1. CAPLUS

CN Phenol, 4-[3-[3-(phenylmethyl)-8-azabicyclo[3.2.1]oct-8-yl]propyl]- (9CI)
(CA INDEX NAME)




RN 338733-13-4 CAPLUS

CN Phenol, 4-[3-[3-[(4-chlorophenyl)methyl]-8-azabicyclo[3.2.1]oct-8-yl]propyl]- (9CI) (CA INDEX NAME)



RN 338733-16-7 CAPLUS


CN Phenol, 4-[3-[3-(phenylmethyl)-8-azabicyclo[3.2.1]oct-8-yl]butyl]- (9CI)
(CA INDEX NAME)



RN 338795-47-4 CAPLUS

CN Phenol, 4-[3-[(3-endo)-3-[(4-chlorophenyl)methyl]-8-azabicyclo[3.2.1]oct-8-yl]propyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> FIL STNGUIDE
COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
55.65	228.41

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE ENTRY	TOTAL SESSION
-7.80	-7.80

CA SUBSCRIBER PRICE

FILE 'STNGUIDE' ENTERED AT 14:33:14 ON 11 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jun 8, 2007 (20070608/UP).

=> d his

(FILE 'HOME' ENTERED AT 14:30:39 ON 11 JUN 2007)

FILE 'REGISTRY' ENTERED AT 14:30:52 ON 11 JUN 2007

L1 STRUCTURE UPLOADED
L2 50 S L1
L3 1336 S L1 FULL

FILE 'CAPLUS' ENTERED AT 14:31:50 ON 11 JUN 2007

L4 217 S L3 FULL
L5 177 S L4 AND PY<2002

FILE 'STNGUIDE' ENTERED AT 14:33:14 ON 11 JUN 2007

=> log y
COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
0.24	228.65

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE ENTRY	TOTAL SESSION
0.00	-7.80

CA SUBSCRIBER PRICE

Connection closed by remote host